ENDRA Life Sciences (NASDAQ:NDRA) Trading Up 6.5% – Time to Buy?

ENDRA Life Sciences Inc. (NASDAQ:NDRA)’s share price shot up 6.5% on Friday . The company traded as high as $6.37 and last traded at $6.05. Approximately 20,582 shares traded hands during trading, a decline of 50% from the average session volume of 41,006 shares. The stock had previously closed at $5.68.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Ascendiant Capital Markets dropped their target price on ENDRA Life Sciences from $27.00 to $25.00 and set a “buy” rating for the company in a research note on Monday, June 1st. Weiss Ratings lowered ENDRA Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 13th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, ENDRA Life Sciences has a consensus rating of “Hold” and a consensus price target of $25.00.

ENDRA Life Sciences Trading Up 6.5%

The company has a market capitalization of $9.07 million, a PE ratio of -0.95 and a beta of -0.05. The company’s 50 day moving average price is $4.93 and its 200-day moving average price is $4.72.

ENDRA Life Sciences (NASDAQ:NDRA) last issued its earnings results on Friday, August 14th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.21. As a group, analysts predict that ENDRA Life Sciences Inc. will post -4.11 earnings per share for the current year.

Hedge Funds Weigh In On ENDRA Life Sciences

An institutional investor recently bought a new position in ENDRA Life Sciences stock. Citizens Financial Group Inc. RI bought a new position in shares of ENDRA Life Sciences Inc. (NASDAQ:NDRA) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 28,400 shares of the company’s stock, valued at approximately $151,000. Citizens Financial Group Inc. RI owned approximately 2.24% of ENDRA Life Sciences as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 1.19% of the company’s stock.

About ENDRA Life Sciences

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.